WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 03 July 2025
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Dr Karmen Joller
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО Minister of Social Affairs
Head office:
Ministry of Social Affairs
UN City, Marmorvej 51, Suur-Ameerika 1 Tallinn 10129
DK-2100 Copenhagen Ø, Denmark Estonia
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected]
Website: https://www.who.int/europe
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Madam,
I am writing to invite you or your delegated representative to take part in an online bilateral
consultation on the potential configuration of the WHO Regional Office for Europe (WHO/Europe)’s
presence in your country. This consultation is expected to take place in the coming weeks. My team
will be in touch with your office to find the most suitable time for you.
This consultation follows an initial discussion with your country’s national counterpart that took place
in June 2025. These discussions come at a pivotal moment for WHO and its Member States. In a
context marked by increasing geopolitical complexity, shifting health needs, financial challenges and
heightened expectations of public sector performance, it is more critical than ever that we align our
efforts to strengthen health systems and improve outcomes for the populations that we serve.
In this spirit, WHO/Europe is undertaking a Region-wide reassessment of its models of collaboration,
with particular focus on how our presence in countries can be most effectively configured to support
national priorities.
This effort is aligned with the evolving structures of both WHO/Europe and WHO headquarters. It is
firmly rooted in the priorities of Member States, as well as in the objectives of the Fourteenth General
Programme of Work, 2025–2028 (GPW 14) and the draft of the second European Programme of Work,
2026–2030 (EPW2). The process is also guided by principles endorsed during the recent Standing
Committee of the Regional Committee for Europe Subgroup Meeting on Country Work.
We see this as an opportunity to explore jointly how we can amplify the impact of our shared efforts,
leveraging WHO/Europe’s technical leadership and the Government of Estonia’s commitment to
health as a strategic priority. This collaboration is also formulated in the recently signed Country
Cooperation Strategy 2024-2030.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: https://www.who.int/europe
Denmark
Please find attached the initial Concept Note on the Review of WHO Country Offices in EU Member
States.
Thank you for your attention to this important matter, and I look forward to your engagement in the
consultation process.
Yours very truly,
Dr Hans Henri P. Kluge
Regional Director
Encls:
Concept Note on the Review of WHO Country Offices in EU Member States
Copy for information to:
Mr Margus Tsahkna, Minister of Foreign Affairs, Ministry of Foreign Affairs, Tallinn, Estonia
Ms Agne Nettan-Sepp, Head, European Union Affairs and International Co-operation Department, Ministry of
Social Affairs, Tallinn, Estonia
Ms Helen Sõber, Adviser, European Union Affairs and International Co-operation Department, Ministry of
Social Affairs, Tallinn, Estonia
H.E. Ms Riia Salsa-Audiffren, Ambassador Representative of the Republic of Estonia, Permanent Mission of
the Republic of Estonia to the United Nations Office and other international organizations in Geneva,
Switzerland
H.E. Mr Andre Pung, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia,
Denmark
Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Tallinn, Estonia
–2–
Saatja: "Correspondence of the WHO Regional Director for Europe" <
[email protected]>
Saaja: "Karmen Joller - SOM" <
[email protected]>, "Agne Nettan-Sepp - SOM" <
[email protected]>, "Helen Sõber - SOM" <
[email protected]>
Teema: Letter from the WHO Regional Director for Europe to the Minister of Social Affairs of Estonia
Kuupäev: 2025-07-03 11:33
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Dear Sir, Dear Madam,
With assurances of the highest consideration of this office, please find
attached the letter from Dr Hans Henri P. Kluge, the WHO Regional Director
for Europe, addressed to Dr Karmen Joller, the Minister of Social Affairs
of Estonia.
We would be grateful if the letter could be transmitted through your good
offices.
Yours sincerely,
Office of the Regional Director
World Health Organization Regional Office for Europe
UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark
Phone: +45 4533 6675
Web: <https://www.who.int/europe/home> WHO/Europe | Home
Concept Note: Review of WHO Country Offices in EU Member States
Executive Summary
This concept note outlines WHO/EURO’s strategic approach to reviewing its presence in EU Member States, as
part of the broader regional restructuring aligned with the EPW2 reform timeline and major financial
constraints resulting in decreased budget envelope across the Region in 2026/27. Informed by internal
consultations, financial reviews, and stakeholder feedback, the document confirms the adoption of a Hybrid
Model as the most appropriate and flexible engagement strategy. Under this model, WHO’s 13 EU Country
Offices will transition into one of three operational modalities, unless alternative sources of funding can be
identified.
Regional Office Engagement (for Countries with mature systems and strategic-level collaboration),
Liaison Officer Model (for strategic visibility with low footprint), or
Multi-country WR Model (for regional coordination and synergy)
These transitions will be guided by technical, financial, and political assessments and supported by a structured
engagement process and consultations with Member States. Further, this approach builds on discussions with
internal stakeholders and the SCRC Sub-group on Country Work, which supported a transparent, context-
specific process for engagement decisions
The proposed timeline aligns with WHO’s regional reform agenda, allowing for country-specific consultations
and implementation between April and December 2025. This ensures a smooth, accountable, and context-
sensitive realignment of WHO’s presence in Europe and countries at the center of our work.
Background
As part of the ongoing strategic realignment process in WHO/EURO in the current financial context, this note
proposes a strategic review of collaboration modalities in EU countries. These countries feature strong national
health systems, deep EU integration, and close coordination with EU agencies, requiring a differentiated
engagement approach that ensures financial sustainability and political relevance.
The country presence frameworks and models endorsed at RC72 in 2022 offer a foundation for restructuring.
This strategic review is not only driven by resource optimization but must also consider the purpose,
effectiveness, and strategic impact of WHO’s presence in each country.
Consultations with internal stakeholders have emphasized that a “one-size-fits-all” approach is neither
operationally sound nor politically viable. EU Member States vary considerably in health sector priorities,
reform capacity, and expectations of WHO support. Therefore, a Hybrid Model has emerged as the most
appropriate and flexible strategy. Building on the CPCP model, expanding its flexibility through strategic use of
Liaison Officers and multi-country mechanisms, this model enables flexibility while ensuring relevance,
accountability, and strategic alignment.
Strategic Role of WHO Presence
Despite ongoing fiscal constraints, maintaining a WHO presence in EU countries remains both technically
critical and strategically vital. Country offices serve as essential platforms for:
1
Aligning with national health reforms and effectively implementing EU-funded initiatives such as
EU4Health.
Preserving WHO’s visibility and influence, especially in an era of rising populism and institutional
competition.
Mitigating reputational risks, including challenges to WHO’s relevance by Member States and potential
funding consequences from bodies like the European Commission.
A sudden or poorly coordinated withdrawal could erode WHO’s leadership standing and credibility—triggering
serious consequences at both regional and global levels.
To address this while remaining responsive and sustainable, a Hybrid Model is proposed as the core strategic
framework. This model ensures:
Tailored engagement aligned with each country’s specific technical, political, and financial realities.
Sustained WHO presence where it is essential for national reforms and EU project implementation.
Optimized resource utilization, balancing visibility with operational efficiency.
Mitigation of political risks and reinforcement of WHO’s organizational credibility and trust with partners.
Proposed Presence Models
Considering the critical role country offices play and the need for adaptable solutions, WHO/EURO proposes to
recalibrate its presence across EU Member states through three structured models, detailed below:
1. Regional Office engagement
Overview: WHO reduces in-country presence, transitioning coordination to the Regional Office using strategic
desk officers and WHO country counterparts. Note: this is already the case for a number of EU countries.
Rationale: EU countries generally possess self-sufficient health systems, reducing the need for a permanent
WHO presence.
Strategic Benefits:
Promotes consistency in messaging and operations across EU Member States.
Aligns with successful models already in place with a number of EU countries.
Offers substantial cost savings in terms of physical infrastructure and staffing.
Risks and Additional Considerations (from consultation feedback):
High political sensitivity: May be perceived as WHO retreating from Europe, risking reputational
damage.
Could weaken WHO's ability to implement key donor-funded initiatives like EU4Health.
May reduce strategic collaboration with the European Commission.
2. Transition to a Liaison Officer Model
Overview: WHO transitions from full-fledged offices to in-country Liaison Officers.
Rationale: Retains strategic visibility and national engagement while reducing costs.
Strategic Benefits:
Maintains WHO's national footprint.
Enables technical cooperation and real-time policy advice with minimal overhead.
May be politically more acceptable than full withdrawal.
2
Risks and Comments-Based Considerations:
Requires well-defined roles and strong technical support.
May weaken WHO's role in implementation-heavy contexts unless paired with strong regional support.
Perceived underinvestment could impact trust.
3. Integration into a Multi-country WHO Representative (WR) Model
Overview: A WR oversees multiple EU countries, supported by a strategic desk officer at the Regional Office.
Rationale: Optimizes resource use while retaining regional-level technical coordination.
Strategic Benefits:
Facilitates regional synergy and thematic collaboration (e.g., digital health, workforce).
Reduces duplication of administrative functions.
Ensures strategic coherence under shared leadership.
Risks and Enhanced Considerations:
Must group countries thoughtfully to maintain responsiveness.
Cultural diversity and national priorities may challenge central coordination.
Risk of being seen as a downgraded presence.
Implementa on: Country-Specific Model Determina on
To ensure that WHO’s presence in EU Member States remains strategically relevant, financially viable, and
politically acceptable, WHO/EURO will undertake a structured, country-by-country process to determine the
most appropriate operating model. These strategic decisions will be guided by a combination of performance
evidence, engagement history, and contextual considerations shared during internal and Member State
consultations. This process will be guided by the following actions:
1. Comprehensive Internal Assessment and Preparation
Conduct financial, legal, programmatic, and political risk assessment.
Evaluate technical cooperation effectiveness and office performance, including return on investment from
BASE, EOA, and donor-funded initiatives.
Identify countries preliminarily suited for each model.
Develop a risk mitigation plan to proactively manage potential political sensitivities and reputational risks.
Engage with staff at relevant country offices to discuss implications and transition considerations.
2. Structured Member State Engagement
Targeted dialogues with Member States and key national stakeholders to validate the operational model
most appropriate to their context.
Clearly present rationale, benefits, and implications for each model, and seek government input and
endorsement.
Ensure transparent communication across all engagement levels.
3. Transition and Realignment
Jointly implement transitions with MS agreement.
Redeploy staff where relevant and ensure continuity of priority programs.
Finalize model-specific support mechanisms and staff arrangements (e.g., desk officer teams, Liaison
Officer profiles).
Monitor, review, and adapt based on results.
3
Proposed meline
Aligned with WHO-wide reform efforts and the broader EPW2 process.
Alignment with EPW2
Phase Activities Timeline
Steps
• Share Draft Concept Note with WRs in EU countries
1. Internal Step 2: Review core
• Virtual WR consultation April 2025
Consultation functions
• Collect written and verbal feedback
• Country-level dialogue with MS
2. Stakeholder • Discuss potential collaboration models
May-June 2025 Step 3: Develop structure
Engagement • Finalize identification of appropriate engagement
model
• Transition plan by country
3. Transition June – August
• HR and legal review Step 4: Plan workforce
Planning 2025
• Develop support mechanisms (liaison, desk teams)
• Begin office transitions
4. Phased • Staff redeployment September – Step 5: Implement the
Implementation • Communications and monitoring December 2025 approved plan
• Review and adapt
WHO/Europe looks forward to continuing this dialogue with each EU Member State and jointly identifying the
best model to support national priorities and shared public health objectives
4